New Economy Portfolio
..bought a stock that is trading like it wants to move much higher soon. For folks that missed my $SYN alert at $2.20 last week (it’s $3.00 now) this stock is near the same price that stock was at $2.20 range before heading higher. Lots of catalysts here moving forward. A licensing deal by YE, Updated Ph 1 data at HepDart 2015 2nd week of December, also expecting word from FDA on IND filing for HBV, Ph 2 studies to commence in 2016. This company which has a pro drug similar to Gilead’s Tenofovir has been discussed as being better tolerated that the gold standard. Company has a market cap under $60m and bought CMX-157 from Chimerix (2B marketcap).
52wk low is $1.05 & 52wk high is $6.28. Alert..bought $CTRV at $2.13 in the New Economy Portfolio with a 15% (Full) position.
This stock has excellent prospects moving forward.
ContraVirPharma: #HepatitisB is the next frontier! $CTRV CEO in @Bloomberg ‘Hepatitis Quest Moves From C to B Under Ex-Gilead Leaders’ http://t.co/sgwuyOntBn
@ContraVirPharma: We plan to file an IND for CMX157 to treat #HBV before year-end 2015, Ph 2 Study to commence in 2016 http://t.co/bDjUpIv3Mr
$CTRV Public Offering Results in $15 Million of Gross Proceeds - @DavidBautz >> https://t.co/qSPOEYPx9X
(Did the offering at $3/share. Price now at $2.15)
The Life Sciences Report-$CTRV ..http://bit.ly/1RdXAJr
$CTRV..October Presentation Slides.. http://bit.ly/1QPHR3Z
$CTRV..Bio-Investor Forum Webcast.. http://bit.ly/1Nlr1aA
Going to do an Audio DD post later today on this stock. Disclaimer: http://bit.ly/OlN9DB